Pharmaceutical House+ (შპს ფარმაცევტული სახლი +)

panel 2026-09-21Ask

as filed · GEL, thousands

Line item	2017	2018	2019	2020	2021	2022	2023	CAGR
Total Revenue	46,519	50,112	35,960	40,348	54,693	65,463	61,646	+4.8%
Total COGS	37,017	38,931	27,865	33,816	46,935	53,078	52,825	+6.1%
Gross Profit	9,502	11,180	8,095	6,532	7,758	12,385	8,821	-1.2%
Gross Margin	20.4%	22.3%	22.5%	16.2%	14.2%	18.9%	14.3%
	3,196	8,036	6,035	7,462	10,972	15,044	20,493	+36.3%
EBITDA	6,306	3,145	2,061	930	3,213	2,659	11,672	nmf
EBITDA Margin	13.6%	6.3%	5.7%	2.3%	5.9%	4.1%	18.9%
Total D&A	350	390	227	292	508	664	983	+18.8%
EBIT / Operating Income	5,957	2,754	1,834	1,222	3,722	3,323	12,655	nmf
Total Interest Income	0	22	48	158	0	0	0	nmf
Total Interest Expense	385	368	456	1,127	1,379	1,451	1,736	+28.5%
	0	98	194	860	3,866	1,641	3,150	nmf
Profit Before Tax	5,572	2,310	1,232	3,051	1,235	3,133	11,241	nmf
Total Income Tax	0	0	0	30	0	0	2	-58.5%
Net Profit / (Loss)	1,460	2,290	1,044	3,296	1,621	3,133	11,243	nmf
Net Margin	3.1%	4.6%	2.9%	8.2%	3.0%	4.8%	18.2%

Pharmaceutical House+